Trivariate Linear Regression and Machine Learning Prediction of Possible Roles of Efflux Transporters in Estimated Intestinal Permeability Values of 301 Disparate Chemicals.
暂无分享,去创建一个
[1] M. Shimizu,et al. Machine Learning Prediction of the Three Main Input Parameters of a Simplified Physiologically Based Pharmacokinetic Model Subsequently Used to Generate Time-Dependent Plasma Concentration Data in Humans after Oral Doses of 212 Disparate Chemicals. , 2021, Biological & pharmaceutical bulletin.
[2] M. Shimizu,et al. An Updated In Silico Prediction Method for Volumes of Systemic Circulation of 323 Disparate Chemicals for Use in Physiologically Based Pharmacokinetic Models to Estimate Plasma and Tissue Concentrations after Oral Doses in Rats. , 2021, Chemical research in toxicology.
[3] K. Funatsu,et al. Prediction of permeability across intestinal cell monolayers for 219 disparate chemicals using in vitro experimental coefficients in a pH gradient system and in silico analyses by trivariate linear regressions and machine learning. , 2021, Biochemical pharmacology.
[4] X. Chu,et al. Absorption, Metabolism, Distribution, and Excretion of Letermovir. , 2021, Current drug metabolism.
[5] A. Dahan,et al. Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation , 2021, Pharmaceutics.
[6] M. Shimizu,et al. In Silico Prediction of Input Parameters for Simplified Physiologically Based Pharmacokinetic Models for Estimating Plasma, Liver, and Kidney Exposures in Rats after Oral Doses of 246 Disparate Chemicals. , 2021, Chemical research in toxicology.
[7] A. Falcão,et al. A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration. , 2020, International journal of pharmaceutics.
[8] C. Jang,et al. ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan , 2020, Archives of Pharmacal Research.
[9] Y. Fujii,et al. Effects of perfluoroalkyl carboxylic acids on the uptake of sulfobromophthalein via organic anion transporting polypeptides in human intestinal Caco-2 cells , 2020, Biochemistry and biophysics reports.
[10] M. Shimizu,et al. Physiologically Based Pharmacokinetic Models Predicting Renal and Hepatic Concentrations of Industrial Chemicals after Virtual Oral Doses in Rats. , 2020, Chemical research in toxicology.
[11] N. Vermeulen,et al. Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates , 2020, Archives of Toxicology.
[12] M. Shimizu,et al. Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide 1B1. , 2020, Drug metabolism and pharmacokinetics.
[13] M. Shimizu,et al. Determination and prediction of permeability across intestinal epithelial cell monolayer of a diverse range of industrial chemicals/drugs for estimation of oral absorption as a putative marker of hepatotoxicity , 2020, Toxicology reports.
[14] Michaela Bairlein,et al. Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies , 2019, European Journal of Drug Metabolism and Pharmacokinetics.
[15] Siyi Pan,et al. Structure affinity relationship and docking studies of flavonoids as substrates of multidrug-resistant associated protein 2 (MRP2) in MDCK/MRP2 cells. , 2019, Food chemistry.
[16] Zhe-Sheng Chen,et al. Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. , 2019, Biochemical pharmacology.
[17] J. Kort,et al. Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir , 2019, The Journal of Pharmacology and Experimental Therapeutics.
[18] Ricardo de Carvalho Cavalli,et al. ABCG2 c.421C>A polymorphism alters nifedipine transport to breast milk in hypertensive breastfeeding women. , 2019, Reproductive toxicology.
[19] J. Beijnen,et al. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice. , 2019, International journal of pharmaceutics.
[20] T. Dalla Costa,et al. Population pharmacokinetic modeling to establish the role of P‐glycoprotein on ciprofloxacin distribution to lung and prostate following intravenous and intratracheal administration to Wistar rats , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[21] H. Yamazaki,et al. Plasma and Hepatic Concentrations of Chemicals after Virtual Oral Administrations Extrapolated Using Rat Plasma Data and Simple Physiologically Based Pharmacokinetic Models. , 2018, Chemical research in toxicology.
[22] H. Yamazaki,et al. Suitable albumin concentrations for enhanced drug oxidation activities mediated by human liver microsomal cytochrome P450 2C9 and other forms predicted with unbound fractions and partition/distribution coefficients of model substrates , 2018, Xenobiotica; the fate of foreign compounds in biological systems.
[23] Takako Shimizu,et al. Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans , 2018, Drug Metabolism and Disposition.
[24] Christine M. Madla,et al. P‐glycoprotein expression in the gastrointestinal tract of male and female rats is influenced differently by food , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[25] G. Ponchel,et al. Intestinal permeability determinants of norfloxacin in Ussing chamber model , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[26] Li Yang,et al. Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo , 2018, Cellular Physiology and Biochemistry.
[27] Imad Hanna,et al. Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition , 2018, Xenobiotica; the fate of foreign compounds in biological systems.
[28] K. Fujita,et al. Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2. , 2017, Drug metabolism and pharmacokinetics.
[29] P. Mismetti,et al. In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition , 2018, European Journal of Drug Metabolism and Pharmacokinetics.
[30] Gilberto Alves,et al. Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors , 2017, Drug Metabolism and Disposition.
[31] P. Trouillas,et al. Single nucleotide polymorphisms of ABCC2 modulate renal secretion of endogenous organic anions , 2017, Biochemical pharmacology.
[32] K. Maeda,et al. Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. , 2017, Journal of pharmaceutical sciences.
[33] M. Taguchi,et al. In Vitro P-Glycoprotein-Mediated Transport of Tadalafil: A Comparison with Sildenafil. , 2017, Biological & pharmaceutical bulletin.
[34] Maria M. Posada,et al. Prediction of Transporter‐Mediated Drug‐Drug Interactions for Baricitinib , 2017, Clinical and translational science.
[35] Mark D. Johnson,et al. In vitro and physiologically‐based pharmacokinetic based assessment of drug–drug interaction potential of canagliflozin , 2017, British journal of clinical pharmacology.
[36] Yukio Kato,et al. P-Glycoprotein in skin contributes to transdermal absorption of topical corticosteroids. , 2017, International journal of pharmaceutics.
[37] A. Kappo,et al. Intestinal transport and absorption of bioactive phenolic compounds from a chemically characterized aqueous extract of Athrixia phylicoides. , 2017, Journal of ethnopharmacology.
[38] A. Rostami-Hodjegan,et al. Caco‐2 cells – expression, regulation and function of drug transporters compared with human jejunal tissue , 2017, Biopharmaceutics & drug disposition.
[39] R. Hegele,et al. Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters. , 2017, Molecular pharmaceutics.
[40] D. Kowalski,et al. Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects , 2016, Clinical pharmacology in drug development.
[41] Y. Miyamoto,et al. Identification of Transporters Involved in Beraprost Sodium Transport In Vitro , 2017, European Journal of Drug Metabolism and Pharmacokinetics.
[42] Masaki Kobayashi,et al. Characterization of loxoprofen transport in Caco‐2 cells: the involvement of a proton‐dependent transport system in the intestinal transport of loxoprofen , 2016, Biopharmaceutics & drug disposition.
[43] D. Parasrampuria,et al. Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine , 2016, British journal of clinical pharmacology.
[44] Zhixia Qiu,et al. Pharmacokinetic effects of curcumin on docetaxel mediated by OATP1B1, OATP1B3 and CYP450s. , 2016, Drug metabolism and pharmacokinetics.
[45] P. Myllynen,et al. The xenoestrogens, bisphenol A and para-nonylphenol, decrease the expression of the ABCG2 transporter protein in human term placental explant cultures , 2016, Molecular and Cellular Endocrinology.
[46] A. D. Rodrigues,et al. Diclofenac and Its Acyl Glucuronide: Determination of In Vivo Exposure in Human Subjects and Characterization as Human Drug Transporter Substrates In Vitro , 2016, Drug Metabolism and Disposition.
[47] S. Misaka,et al. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3. , 2016, Molecular pharmaceutics.
[48] B. Brodin,et al. IPEC-J2 MDR1, a Novel High-Resistance Cell Line with Functional Expression of Human P-glycoprotein (ABCB1) for Drug Screening Studies. , 2016, Molecular pharmaceutics.
[49] Thomas J. Raub,et al. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft , 2015, Drug Metabolism and Disposition.
[50] Mahmoud S. Assaf,et al. Pomalidomide: Evaluation of cytochrome P450 and transporter‐mediated drug–drug interaction potential in vitro and in healthy subjects , 2015, Journal of clinical pharmacology.
[51] P. McNaughton,et al. Inflammatory and neuropathic pain are rapidly suppressed by peripheral block of hyperpolarisation-activated cyclic nucleotide-gated ion channels , 2014, PAIN®.
[52] Y. Daali,et al. Role of P‐glycoprotein in the Uptake/Efflux Transport of Oral Vitamin K Antagonists and Rivaroxaban through the Caco‐2 Cell Model , 2013, Basic & clinical pharmacology & toxicology.
[53] J. Dingemanse,et al. Investigation of the Effects of Ketoconazole on the Pharmacokinetics of Macitentan, a Novel Dual Endothelin Receptor Antagonist, in Healthy Subjects , 2013, Clinical Pharmacokinetics.
[54] J. Lieberman,et al. Exploratory study on association of genetic variation in TBC1D1 with antipsychotic‐induced weight gain , 2013, Human psychopharmacology.
[55] Sara E. Mansell,et al. Absence of both MDR1 (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Transporters Significantly Alters Rivaroxaban Disposition and Central Nervous System Entry , 2013, Basic & clinical pharmacology & toxicology.
[56] K. Kang,et al. Menadione serves as a substrate for P-glycoprotein: implication in chemosensitizing activity , 2013, Archives of pharmacal research.
[57] S. Yamada,et al. Characterization of the carrier‐mediated transport of ketoprofen, a nonsteroidal anti‐inflammatory drug, in rabbit corneal epithelium cells , 2013, The Journal of pharmacy and pharmacology.
[58] K. Kang,et al. Repeated dosing of piperine induced gene expression of P‐glycoprotein via stimulated pregnane‐X‐receptor activity and altered pharmacokinetics of diltiazem in rats , 2012, Biopharmaceutics & drug disposition.
[59] N. Takahashi,et al. Drug interaction between lenalidomide and itraconazole , 2012, American journal of hematology.
[60] D. Surry,et al. Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug–drug interaction to support regulatory submissions , 2011, Xenobiotica; the fate of foreign compounds in biological systems.
[61] Grant T. Generaux,et al. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins , 2011, Xenobiotica; the fate of foreign compounds in biological systems.
[62] M. J. Hemmer,et al. Application of protein expression profiling to screen chemicals for androgenic activity. , 2011, Aquatic toxicology.
[63] X. An,et al. The Phosphodiesterase-5 Inhibitor Vardenafil Is a Potent Inhibitor of ABCB1/P-Glycoprotein Transporter , 2011, PloS one.
[64] P. Kwan,et al. In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein. , 2010, Life sciences.
[65] L. Benet,et al. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. , 2009, Journal of pharmaceutical sciences.
[66] K. Naruhashi,et al. Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[67] P. Neuvonen,et al. ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.
[68] G. Mishra,et al. Enhanced Corneal Absorption of Erythromycin by Modulating P-Glycoprotein and MRP Mediated Efflux with Corticosteroids , 2009, Pharmaceutical Research.
[69] Y. Daali,et al. Lack of interaction of the NMDA receptor antagonists dextromethorphan and dextrorphan with P-glycoprotein. , 2008, Current drug metabolism.
[70] T. Fujita,et al. Oseltamivir (Tamiflu) Efflux Transport at the Blood-Brain Barrier via P-Glycoprotein , 2008, Drug Metabolism and Disposition.
[71] E. Fuse,et al. P-glycoprotein limits the brain penetration of olopatadine hydrochloride, H1-receptor antagonist. , 2008, Drug metabolism and pharmacokinetics.
[72] K. Ueno,et al. Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals , 2008, Cancer Chemotherapy and Pharmacology.
[73] H. Barennes,et al. Increased uptake of quinine into the brain by inhibition of P-glycoprotein. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[74] B. Hagenbuch. Cellular entry of thyroid hormones by organic anion transporting polypeptides. , 2007, Best practice & research. Clinical endocrinology & metabolism.
[75] T. Sakaeda,et al. Haloperidol is an inhibitor but not substrate for MDR1/P‐glycoprotein , 2006, The Journal of pharmacy and pharmacology.
[76] M. Fromm,et al. Characterization of β‐adrenoceptor antagonists as substrates and inhibitors of the drug transporter P‐glycoprotein 1 , 2006 .
[77] L. O’Driscoll,et al. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer , 2006, Cancer Chemotherapy and Pharmacology.
[78] Alfred H. Schinkel,et al. BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) TRANSPORTS FLUOROQUINOLONE ANTIBIOTICS AND AFFECTS THEIR ORAL AVAILABILITY, PHARMACOKINETICS, AND MILK SECRETION , 2006, Drug Metabolism and Disposition.
[79] T. Olah,et al. Development of an on-line extraction turbulent flow chromatography tandem mass spectrometry method for cassette analysis of Caco-2 cell based bi-directional assay samples. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[80] H. Gutmann,et al. Thalidomide does not interact with P-glycoprotein , 2006, Cancer Chemotherapy and Pharmacology.
[81] Ismael Zamora,et al. pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[82] Y. Konishi,et al. Intestinal absorption of p-coumaric and gallic acids in rats after oral administration. , 2004, Journal of agricultural and food chemistry.
[83] Antony D'Emanuele,et al. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[84] M. Aburada,et al. Permeability of the flavonoids liquiritigenin and its glycosides in licorice roots and davidigenin, a hydrogenated metabolite of liquiritigenin, using human intestinal cell line Caco-2. , 2003, Journal of ethnopharmacology.
[85] Thomas Walle,et al. Cellular Uptake and Efflux of the Tea Flavonoid (-)Epicatechin-3-gallate in the Human Intestinal Cell Line Caco-2 , 2003, Journal of Pharmacology and Experimental Therapeutics.
[86] M. Shimizu,et al. Transepithelial Transport of Ferulic Acid by Monocarboxylic Acid Transporter in Caco-2 Cell Monolayers , 2003, Bioscience, biotechnology, and biochemistry.
[87] R. Kim,et al. Interaction of Morphine, Fentanyl, Sufentanil, Alfentanil, and Loperamide with the Efflux Drug Transporter P-glycoprotein , 2002, Anesthesiology.
[88] G. Amidon,et al. Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. , 2002, Journal of pharmaceutical sciences.
[89] M. Fromm,et al. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.
[90] R. Kim,et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.
[91] B. Masereel,et al. P-glycoprotein inhibition by glibenclamide and related compounds , 1999, Pflügers Archiv.
[92] M. Fukuda,et al. A leukotriene receptor antagonist, ONO-1078, modulates drug sensitivity and leukotriene C4 efflux in lung cancer cells expressing multidrug resistance protein. , 1998, Biochemical and biophysical research communications.
[93] D. Clarke,et al. Nonylphenol ethoxylates, but not nonylphenol, are substrates of the human multidrug resistance P-glycoprotein. , 1998, Biochemical and biophysical research communications.
[94] H. Takanaga,et al. Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids. , 1995, Biochemical and biophysical research communications.